Lumefantrine is an antimalarial agent used in combination with artemether for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
- Mechanism
- Curator reviewed
The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. However, available data suggest that lumefantrine inhibits the formation of β-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis.
- Primary indication
- Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas.Curator reviewed · 1 structured indication
- Formula / weight
- C30H32Cl3NO · 528.94 g/mol (avg)
- First approval
- United States, 2009
- Also known as
- Benflumetol · dl-Benflumelol
- Brand names
Resolves to
DYLGFOYVTXJFJP-MYYYXRDXSA-NSMILESCCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1What you can answer from here — as of March 06, 2025
Which drugs share a target with Lumefantrine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account